1. Home
  2. PBYI vs PLAO Comparison

PBYI vs PLAO Comparison

Compare PBYI & PLAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • PLAO
  • Stock Information
  • Founded
  • PBYI 2010
  • PLAO 2021
  • Country
  • PBYI United States
  • PLAO Cayman Islands
  • Employees
  • PBYI N/A
  • PLAO N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • PLAO Blank Checks
  • Sector
  • PBYI Health Care
  • PLAO Finance
  • Exchange
  • PBYI Nasdaq
  • PLAO Nasdaq
  • Market Cap
  • PBYI 126.5M
  • PLAO 119.5M
  • IPO Year
  • PBYI N/A
  • PLAO 2022
  • Fundamental
  • Price
  • PBYI $2.71
  • PLAO $11.60
  • Analyst Decision
  • PBYI Strong Buy
  • PLAO
  • Analyst Count
  • PBYI 1
  • PLAO 0
  • Target Price
  • PBYI $7.00
  • PLAO N/A
  • AVG Volume (30 Days)
  • PBYI 287.1K
  • PLAO 4.8K
  • Earning Date
  • PBYI 10-31-2024
  • PLAO 01-01-0001
  • Dividend Yield
  • PBYI N/A
  • PLAO N/A
  • EPS Growth
  • PBYI N/A
  • PLAO 14.37
  • EPS
  • PBYI 0.18
  • PLAO 0.38
  • Revenue
  • PBYI $219,143,000.00
  • PLAO N/A
  • Revenue This Year
  • PBYI N/A
  • PLAO N/A
  • Revenue Next Year
  • PBYI N/A
  • PLAO N/A
  • P/E Ratio
  • PBYI $14.56
  • PLAO $30.64
  • Revenue Growth
  • PBYI N/A
  • PLAO N/A
  • 52 Week Low
  • PBYI $2.13
  • PLAO $10.97
  • 52 Week High
  • PBYI $7.73
  • PLAO $12.06
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 49.79
  • PLAO 56.13
  • Support Level
  • PBYI $2.55
  • PLAO $11.58
  • Resistance Level
  • PBYI $2.66
  • PLAO $11.62
  • Average True Range (ATR)
  • PBYI 0.12
  • PLAO 0.00
  • MACD
  • PBYI 0.03
  • PLAO -0.00
  • Stochastic Oscillator
  • PBYI 66.67
  • PLAO 47.62

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About PLAO Patria Latin American Opportunity Acquisition Corp.

Patria Latin American Opportunity Acquisition Corp is a blank check company.

Share on Social Networks: